Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast CancerCompleted
NCT03197935Phase 3Updated Oct 26, 2023
Sponsor: Hoffmann-La Roche
Triple-negative Breast Cancer
United States, Australia, Belgium, Brazil, Canada +8 more
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung CancerTerminated
NCT04308785Phase 2Updated Oct 23, 2023
Sponsor: Hoffmann-La Roche
Carcinoma, Small Cell Lung
China
Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-ComtéTerminated
NCT02626377NAUpdated Oct 23, 2023
Sponsor: Centre Hospitalier Universitaire de Besancon
Breast Cancer · Colorectal Cancer · Prostate Cancer · Alzheimer Disease
France
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompleted
NCT03434379Phase 3Updated Oct 23, 2023
Sponsor: Hoffmann-La Roche
Carcinoma, Hepatocellular
United States, Australia, Canada, China, Czechia +12 more
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).Terminated
NCT04404140Phase 1Updated Oct 17, 2023
Sponsor: Hoffmann-La Roche
Castration-Resistant Prostatic Cancer
France, Italy, Spain, Switzerland
A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Completed
NCT02005471Phase 3Updated Oct 17, 2023
Sponsor: Hoffmann-La Roche
Chronic Lymphocytic Leukemia
United States, Australia, Austria, Belgium, Canada +15 more
Evaluation of the Roche Liat Flu/RSV Assay for Management of Influenza in the Emergency DepartmentCompleted
NCT02899065NAUpdated Oct 17, 2023
Sponsor: University of California, Davis
Influenza, Human
United States
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)Completed
NCT04660799Phase 2Updated Oct 12, 2023
Sponsor: Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
China
FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer PatientsCompleted
NCT03721653Phase 2Updated Oct 12, 2023
Sponsor: Gruppo Oncologico del Nord-Ovest
Metastatic Colorectal Cancer
Italy
ctDNA Guided Treatment of Early Resistance to Targeted TreatmentCompleted
NCT04148066NAUpdated Oct 10, 2023
Sponsor: The Netherlands Cancer Institute
Carcinoma, Non-Small-Cell Lung
Netherlands
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)Completed
NCT02611323Phase 1, Phase 2Updated Oct 10, 2023
Sponsor: Hoffmann-La Roche
Non-Hodgkin's Lymphoma
United States, Australia, Italy
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled SyringeCompleted
NCT05569148Phase 3Updated Oct 10, 2023
Sponsor: Hoffmann-La Roche
Neovascular Age-related Macular Degeneration · Diabetic Macular Edema
United States
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective DisorderCompleted
NCT04512066Phase 2Updated Oct 10, 2023
Sponsor: Hoffmann-La Roche
Schizophrenia, Schizoaffective Disorder
United States, Japan, Russia, Ukraine
Molecular Characterization of Penile Cancers in Developing CountriesCompleted
NCT06068998N/AUpdated Oct 5, 2023
Sponsor: Latin American Cooperative Oncology Group
Penile Squamous Cell Carcinoma
Brazil
Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney TransplantationCompleted
NCT00681213Phase 4Updated Sep 22, 2023
Sponsor: University of Miami
Adult Primary Kidney Transplantation
United States
PEnile Cancer Radio- and Immunotherapy CLinical Exploration StudyCompleted
NCT03686332Phase 2Updated Sep 21, 2023
Sponsor: The Netherlands Cancer Institute
Penile Cancer
Netherlands
Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)Terminated
NCT04790916Phase 2Updated Sep 18, 2023
Sponsor: Hoffmann-La Roche
Autoimmune Hepatitis · Autoimmune Chronic Hepatitis
Australia, Canada, Germany, Italy, Netherlands +3 more
Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal TransplantationCompleted
NCT00681343Phase 4Updated Sep 14, 2023
Sponsor: University of Miami
Living-Donor Kidney Transplant
United States
Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)Recruiting
NCT05661188Phase 2Updated Sep 13, 2023
Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Squamous Cell Carcinoma of the Anal Canal
Spain
The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal CancerCompleted
NCT01606098Phase 3Updated Sep 13, 2023
Sponsor: Dutch Colorectal Cancer Group
Colon Cancer · Primary Tumour · Rectal Cancer
Denmark, Netherlands
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714Unknown
NCT03691077Phase 3Updated Sep 6, 2023
Sponsor: Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis · Relapse · Primary Progressive Multiple Sclerosis
France
The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior ChemotherapyCompleted
NCT03559647N/AUpdated Sep 1, 2023
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer (NSCLC)
Germany
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored StudiesCompleted
NCT03842969Phase 3Updated Aug 31, 2023
Sponsor: Hoffmann-La Roche
Huntington Disease
United States, Austria, Canada, Germany, Italy +3 more
Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular RelapseTerminated
NCT03229382Phase 2Updated Aug 16, 2023
Sponsor: Polish Lymphoma Research Group
Mantle Cell Lymphoma
Poland
Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision OncologyCompleted
NCT04389541N/AUpdated Aug 14, 2023
Sponsor: iOMEDICO AG
Advanced Solid Tumors or Hematologic Malignancies
Germany

Previous page Next page